Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Newsletter #2
UC1: Detection of prostate cancer with high accuracy in both the peripheral and transitional zone
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
(Meta)Data Infrastructure for Trustworthy AI
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
The clinical vision and impact of the project
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A regulated pathway for Artificial Intelligence in Medical Imaging
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging[1] has experienced a considerable acceleration. This...
Presentation of partner Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF)
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
Presentation of partner FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE)
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
Presentation of partner Massachusetts General Hospital (The General Hospital Corp) (QTIM)
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
Highlights

Use Cases mapped along the prostate cancer management continuum
Apr 6, 2022
Use Cases mapped along the prostate cancer management continuum in the ProCAncer-I Project

Introducing FUTURE-AI: Best practices for trustworthy AI in medical imaging
Feb 16, 2022
ProCAncer -I Project is part of the five H2020 projects that share the same vision, principles and challenges. These projects are funded under the same Action Line: AI for Health Imaging (Call: H2020-SC1-FA-DTS-2019-1): CHAIMELEON (chaimeleon.eu), EuCanImage...

Our 2nd issue of the ProCAncer-I newsletter has been published!
Jan 25, 2022
Our second winter Newsletter has been released! Read more here: 2nd Winter Newsleter Do not forget to subscribe for our next editions!

System for detection of tumors based on magnetic resonance: prostate analysis (video)
Dec 10, 2021
How could AI improve prostate cancer diagnosis? This video from the research group of prof. Daniele Regge (coordinator of the clinical activities) explains AI application to prostate MRI.
AI tool accurately predicts tumour regrowth in cancer patients https://www.theguardian.com/society/2022/apr/23/cancer-ai-tool-predicts-tumour-regrowth?CMP=share_btn_tw